Target Gene/Pathway Pathway / Gene


Search results


No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related
KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 African trypanosomiasis 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
2 African trypanosomiasis 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
3 African trypanosomiasis 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
4 African trypanosomiasis 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
5 African trypanosomiasis 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
6 AGE-RAGE signaling pathway in diabetic complications 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
7 AGE-RAGE signaling pathway in diabetic complications 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
8 AGE-RAGE signaling pathway in diabetic complications 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
9 AGE-RAGE signaling pathway in diabetic complications 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
10 AGE-RAGE signaling pathway in diabetic complications 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
11 Alcoholic liver disease 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
12 Alcoholic liver disease 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
13 Alcoholic liver disease 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
14 Alcoholic liver disease 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
15 Alcoholic liver disease 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
16 Alzheimer disease 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
17 Alzheimer disease 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
18 Alzheimer disease 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
19 Alzheimer disease 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
20 Alzheimer disease 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
21 Amoebiasis 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
22 Amoebiasis 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
23 Amoebiasis 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
24 Amoebiasis 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
25 Amoebiasis 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
26 C-type lectin receptor signaling pathway 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
27 C-type lectin receptor signaling pathway 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
28 C-type lectin receptor signaling pathway 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
29 C-type lectin receptor signaling pathway 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
30 C-type lectin receptor signaling pathway 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
31 Chagas disease 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
32 Chagas disease 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
33 Chagas disease 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
34 Chagas disease 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
35 Chagas disease 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
36 Coronavirus disease - COVID-19 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
37 Coronavirus disease - COVID-19 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
38 Coronavirus disease - COVID-19 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
39 Coronavirus disease - COVID-19 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
40 Coronavirus disease - COVID-19 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
41 Cytokine-cytokine receptor interaction 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
42 Cytokine-cytokine receptor interaction 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
43 Cytokine-cytokine receptor interaction 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
44 Cytokine-cytokine receptor interaction 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
45 Cytokine-cytokine receptor interaction 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
46 Cytosolic DNA-sensing pathway 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
47 Cytosolic DNA-sensing pathway 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
48 Cytosolic DNA-sensing pathway 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
49 Cytosolic DNA-sensing pathway 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
50 Cytosolic DNA-sensing pathway 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
51 Fluid shear stress and atherosclerosis 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
52 Fluid shear stress and atherosclerosis 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
53 Fluid shear stress and atherosclerosis 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
54 Fluid shear stress and atherosclerosis 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
55 Fluid shear stress and atherosclerosis 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
56 Graft-versus-host disease 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
57 Graft-versus-host disease 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
58 Graft-versus-host disease 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
59 Graft-versus-host disease 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
60 Graft-versus-host disease 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
61 Hematopoietic cell lineage 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
62 Hematopoietic cell lineage 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
63 Hematopoietic cell lineage 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
64 Hematopoietic cell lineage 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
65 Hematopoietic cell lineage 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
66 Herpes simplex virus 1 infection 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
67 Herpes simplex virus 1 infection 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
68 Herpes simplex virus 1 infection 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
69 Herpes simplex virus 1 infection 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
70 Herpes simplex virus 1 infection 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
71 Human cytomegalovirus infection 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
72 Human cytomegalovirus infection 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
73 Human cytomegalovirus infection 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
74 Human cytomegalovirus infection 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
75 Human cytomegalovirus infection 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
76 IL-17 signaling pathway 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
77 IL-17 signaling pathway 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
78 IL-17 signaling pathway 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
79 IL-17 signaling pathway 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
80 IL-17 signaling pathway 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
81 Inflammatory bowel disease 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
82 Inflammatory bowel disease 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
83 Inflammatory bowel disease 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
84 Inflammatory bowel disease 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
85 Inflammatory bowel disease 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
86 Inflammatory mediator regulation of TRP channels 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
87 Inflammatory mediator regulation of TRP channels 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
88 Inflammatory mediator regulation of TRP channels 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
89 Inflammatory mediator regulation of TRP channels 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
90 Inflammatory mediator regulation of TRP channels 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
91 Influenza A 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
92 Influenza A 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
93 Influenza A 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
94 Influenza A 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
95 Influenza A 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
96 Legionellosis 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
97 Legionellosis 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
98 Legionellosis 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
99 Legionellosis 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
100 Legionellosis 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
101 Leishmaniasis 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
102 Leishmaniasis 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
103 Leishmaniasis 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
104 Leishmaniasis 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
105 Leishmaniasis 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
106 Lipid and atherosclerosis 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
107 Lipid and atherosclerosis 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
108 Lipid and atherosclerosis 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
109 Lipid and atherosclerosis 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
110 Lipid and atherosclerosis 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
111 Malaria 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
112 Malaria 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
113 Malaria 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
114 Malaria 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
115 Malaria 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
116 MAPK signaling pathway 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
117 MAPK signaling pathway 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
118 MAPK signaling pathway 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
119 MAPK signaling pathway 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
120 MAPK signaling pathway 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
121 Measles 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
122 Measles 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
123 Measles 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
124 Measles 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
125 Measles 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
126 Necroptosis 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
127 Necroptosis 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
128 Necroptosis 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
129 Necroptosis 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
130 Necroptosis 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
131 NF-kappa B signaling pathway 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
132 NF-kappa B signaling pathway 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
133 NF-kappa B signaling pathway 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
134 NF-kappa B signaling pathway 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
135 NF-kappa B signaling pathway 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
136 NOD-like receptor signaling pathway 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
137 NOD-like receptor signaling pathway 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
138 NOD-like receptor signaling pathway 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
139 NOD-like receptor signaling pathway 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
140 NOD-like receptor signaling pathway 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
141 Non-alcoholic fatty liver disease 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
142 Non-alcoholic fatty liver disease 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
143 Non-alcoholic fatty liver disease 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
144 Non-alcoholic fatty liver disease 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
145 Non-alcoholic fatty liver disease 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
146 Osteoclast differentiation 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
147 Osteoclast differentiation 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
148 Osteoclast differentiation 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
149 Osteoclast differentiation 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
150 Osteoclast differentiation 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
151 Pathogenic Escherichia coli infection 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
152 Pathogenic Escherichia coli infection 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
153 Pathogenic Escherichia coli infection 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
154 Pathogenic Escherichia coli infection 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
155 Pathogenic Escherichia coli infection 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
156 Pathways of neurodegeneration - multiple diseases 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
157 Pathways of neurodegeneration - multiple diseases 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
158 Pathways of neurodegeneration - multiple diseases 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
159 Pathways of neurodegeneration - multiple diseases 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
160 Pathways of neurodegeneration - multiple diseases 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
161 Pertussis 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
162 Pertussis 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
163 Pertussis 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
164 Pertussis 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
165 Pertussis 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
166 Prion disease 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
167 Prion disease 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
168 Prion disease 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
169 Prion disease 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
170 Prion disease 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
171 Rheumatoid arthritis 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
172 Rheumatoid arthritis 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
173 Rheumatoid arthritis 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
174 Rheumatoid arthritis 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
175 Rheumatoid arthritis 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
176 Salmonella infection 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
177 Salmonella infection 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
178 Salmonella infection 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
179 Salmonella infection 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
180 Salmonella infection 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
181 Shigellosis 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
182 Shigellosis 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
183 Shigellosis 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
184 Shigellosis 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
185 Shigellosis 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
186 Th17 cell differentiation 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
187 Th17 cell differentiation 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
188 Th17 cell differentiation 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
189 Th17 cell differentiation 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
190 Th17 cell differentiation 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
191 TNF signaling pathway 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
192 TNF signaling pathway 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
193 TNF signaling pathway 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
194 TNF signaling pathway 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
195 TNF signaling pathway 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
196 Toll-like receptor signaling pathway 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
197 Toll-like receptor signaling pathway 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
198 Toll-like receptor signaling pathway 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
199 Toll-like receptor signaling pathway 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
200 Toll-like receptor signaling pathway 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
201 Tuberculosis 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
202 Tuberculosis 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
203 Tuberculosis 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
204 Tuberculosis 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
205 Tuberculosis 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
206 Type I diabetes mellitus 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
207 Type I diabetes mellitus 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
208 Type I diabetes mellitus 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
209 Type I diabetes mellitus 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
210 Type I diabetes mellitus 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬
211 Yersinia infection 💬
1件: IL1B 💬 Canakinumab 💬 Canakinumab 11件: 46, 54, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
212 Yersinia infection 💬
1件: IL1B 💬 Gevokizumab 💬 Gevokizumab 4件: 41, 50, 56, 269 💬
213 Yersinia infection 💬
1件: IL1B 💬 Lutikizumab 💬 Lutikizumab 3件: 46, 96, 97 💬
214 Yersinia infection 💬
1件: IL1B 💬 Pirfenidone 💬 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
215 Yersinia infection 💬
1件: IL1B 💬 Rilonacept 💬 Rilonacept 5件: 51, 84, 106, 107, 266 💬